
VBI Vaccines Investor Relations Material
Latest events

Fireside Chat
VBI Vaccines

Q1 2024
15 May, 2024

Q4 2023
16 Apr, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from VBI Vaccines Inc
Access all reports
VBI Vaccines Inc., also known as Variation Biotechnologies Inc., is a biopharmaceutical company focused on the development and commercialization of vaccines for infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a commercialized hepatitis B vaccine, and has several vaccine candidates in various stages of development. These include treatments for hepatitis B, glioblastoma, cytomegalovirus, and Zika virus, along with multiple coronavirus vaccine candidates. VBI Vaccines has significant collaborations with entities like GlaxoSmithKline, the National Research Council of Canada, and the Coalition for Epidemic Preparedness Innovations. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
VBIV
Country
🇺🇸 United States